fbpx
QQQ
+ 1.81
292.66
+ 0.61%
DIA
-1.81
302.21
-0.6%
SPY
-0.65
363.79
-0.18%
TLT
-0.49
159.66
-0.31%
GLD
-0.08
169.67
-0.05%

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

August 17, 2020 10:33 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of August 10th – 16th, 2020.

Without further ado, let’s get started.

Yahoo Finance readers, please click here to view full article.

10. Red White & Bloom’s Acquisition of Platinum Vape Will Mark a Positive Inflection Point in the Growth of the American Cannabis Industry

Overvalued and Shareholder Unfriendly Deals Will Start to Be Replaced By Value-Added, Responsible M&A Setting Off the Next Phase of Parabolic Growth in the U.S. Cannabis Sector

Not all mergers and acquisitions are created equal, especially in the cannabis industry. Over the past few years, a number of companies, such as Aurora Cannabis (NYSE:ACB) and iAnthus Holdings (OTCQX:ITHUF), have grossly overpaid for assets, resulting in write-downs and sell-offs. Red White & Bloom (OTCQX:RWBYF) believes that its recent acquisitions have come at much more attractive prices, leading to increased shareholder value.

READ FULL RWB ARTICLE

9. Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics

The Company Has Developed Prototypes of Orally Dissolvable Thin Film for Psilocybin

Revive Therapeutics (OTCPK: RVVTF) announced that under its sponsored research partnership agreement entered with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of Psilocybin, the company has received the first set of orally dissolvable thin film strips initially to be used to deliver Psilocybin and subsequently additional Psychedelic-derived medicines.

READ FULL REVIVE ARTICLE

8. Cantor Raises Canopy Growth Target After Q1 Earnings Call

Canopy’s First-Quarter Results Reflected the Company’s Transition Phase, with a New Organization Structure, Trimmed Strategy and Supply Chain Review

Cantor Fitzgerald analyst Pablo Zuanic maintained a Neutral rating for Canopy Growth (NYSE:CGC), while raising the price target from CDN $25.50 to CDN $27.50. The Canopy Thesis: While the company delivered a sales beat for the first quarter, this was against conservative guidance and its B2B (business-to-business) sales growth lagged the industry, Zuanic said in the note.

READ FULL CANOPY GROWTH ARTICLE

7. CSE CEO: Psychedelics Investing is a Pharma Play

A Canadian Securities Exchange Executive Believes Psychedelics Investment Opportunities at Their Core Relate Most to the Pharmaceutical Industry

As the Canadian Securities Exchange (CSE) moves forward with Psychedelics companies, CSE CEO Richard Carleton said the exchange’s staff have relevant expertise from years of dealing directly with Cannabis Stocks — many of these companies operate in jurisdictions with confusing regulatory frameworks.

READ FULL PSYCHEDELICS INVESTING ARTICLE

6. Red White & Bloom Inks Exclusive Deal with Avicanna to Distribute CBD Topicals and Cosmetics in the U.S.

The Partnership Will Allow Both Companies to Stake a Claim in the Rapidly Expanding $532 Billion Beauty Industry with the Most Advanced and Only Clinically Backed CBD Skin Care Line

Red White & Bloom (OTCQX:RWBYF) and Avicanna (OTCQX:AVCNF) announced via a joint press release that the two companies have struck an exclusive distribution deal that will see RWB distribute Avicanna’s advanced and clinically backed Pura H&W CBD-based cosmetic and topical products in the United States.

READ FULL RED WHITE & BLOOM ARTICLE

5. MindMed Announces Q2 2020 Financial Results

MindMed Reports Strong Cash Position of $24m USD to Execute Multiple Clinical Trials

MindMed (OTCQB:MMEDF), the leading Psychedelic pharmaceutical company, has announced its second-quarter financial results for the three and six months ended June 30, 2020.

READ FULL MINDMED ARTICLE

4. 4 Cannabis Stocks Poised to Profit From Legalization Votes

Marijuana Legalization Initiatives Will Be on the Ballot in a Number of States in November

Cannabis companies have garnered a lot of attention this year following the spikes in sales that accompanied the pandemic. Though there’s still no clarity about when Congress might start weighing legalization at the federal level, adding new states to the legal Marijuana market could lift multi-state operators (MSOs) including Green Thumb (OTCQX:GTBIF), Curaleaf (OTCQX:CURLF), Cresco Labs (OTCQX:CRLBF) and Canopy Growth (NYSE:CGC) to new highs.

READ FULL CANNABIS STOCKS ARTICLE

3. Green Thumb Industries’ Q2 Was “Remarkable”, Says Echelon Capital

Following a Second Quarter He Described as “Remarkable”, Echelon Capital Markets Analyst Andrew Semple Has Raised His Price Target on Green Thumb Industries

In a research update, Semple maintained his “Buy” rating on Green Thumb (OTCQX:GTBIF) but hiked his one-year price target from $21.00 to $25.00, implying a return of 24% at the time of publication.

READ FULL GREEN THUMB ARTICLE

2. First-of-its-Kind Clinical Trial to Study Psychedelic Treatments for PTSD in Veterans

The First Compound to be Studied Will Be Psilocybin, a Psychedelic Prodrug Compound That Can Be Produced By More Than 200 Species of Mushrooms

Psychedelics-based treatments developer NeuroPharm, a subsidiary of publicly traded Mydecine Innovations (OTCQX:MYCOF), recently announced it would be collaborating with the Leiden University Medical Center of The Netherlands (LUMC) on clinical trials for the treatment of posttraumatic stress disorder (PTSD) in veterans.

READ FULL MYDECINE ARTICLE

1. Analysts Update Ratings and Price Targets on Trulieve Following Blockbuster Q2 Earnings

In Addition to Trulieve’s Stellar Q2 Earnings, the Company Also Raised its Fiscal 2020 Revenue Guidance From $380 Million – $400 Million to $465 Million – $485 Million

While 2020 may certainly be a year to forget for many Americans, it’s been a breakout year for Trulieve Cannabis (OTCQX:TCNNF), and the company’s very happy shareholders. Trulieve crushed Wall Street’s expectations after posting Q2 2020 revenue and adjusted EBITDA of $120.8 million and $60.5 million, Respectively

READ FULL TRULIEVE ARTICLE

Photo by ryan lange on Unsplash


Related Articles

Pure Sunfarms Inks Supply Deal With Shoppers Drug Mart

Pure Sunfarms opted to supply Shoppers Drug Mart Inc's customers with its cannabis products. The Village Farms International Inc. (NASDAQ: VFF) (TSX: VFF) subsidiary teamed up with the Canadian retail pharmacy chain to provide consumers with Pure Sunfarms' dried flower products. read more

Cannabis Movers & Shakers: Cannabis Growth Opportunity, Bhang, CanaFarma Hemp, Amfil Technologies

Here is a summary of the latest company shakeups within the cannabis industry. 3 Execs Exit Cannabis Growth Opportunity Investment company Cannabis Growth Opportunity Corporation (CSE: CGOC) has parted ways with several executives. read more

Earnings Update: Vireo, Rubicon, Flower, Planet 13, Driven Deliveries, Decibel, Pure Harvest

Vireo Health Revenue Spikes, New Stores To Open By Q1 2021 read more

A Weed-Infused Cooking Class For Thanksgiving? One Cannabis ETF's Unique Marketing Strategy

ETFMG has come up with a very interesting marketing idea. read more

Jay-Z Inks Largest Cannabis SPAC Deal Ever With Subversive Capital, Roc Nation, Caliva, Left Coast Ventures

Music industry mogul Jay-Z is set to join a newly formed cannabis company that's expected to become the largest in California. read more